Publications found:
105,748
Sort by:
Biofuel Industry in the United States
US$ 325.00
... from corn grain and biodiesel are the only biofuels produced in the United States on an industrial scale. Most of the four billion gallons of ... an in-depth coverage for this industry in the United States in its latest research report – Biofuel Industry in the United States. This 100 page report looks at the ...
June 2012
145 pages
Profiling the US Petroleum Refining Industry
US$ 350.00
... low quality crude oils. Aruvian Research’s report – Profiling the US Petroleum Refining Industry – analyzes the US petroleum refining industry starting from the basics. The report ...
June 2012
100 pages
Analyzing the Energy Industry in United States
US$ 450.00
... as supply strategies globally. Aruvian's R'search’s report – Analyzing the Energy Industry in United States - analyzes the scope of American energy production from varied traditional sources as well as the ...
June 2012
700 pages
Analyzing the Nuclear Power Industry in the US
US$ 400.00
The United States is the world's largest supplier of commercial nuclear power. In recent years, there has been a renewed interest in nuclear power in the US. This has been facilitated in part ...
June 2012
200 pages
Analyzing Light-Duty Hybrid-Electric Vehicles in the US
US$ 400.00
... electric vehicles are finally being sold commercially by manufacturers. The demand for light-duty hybrid-electric vehicles in the United States ... . Aruvians Rsearch analyzes the Light Duty Hybrid Electric vehicles market in the US in its research offering Analyzing Light Duty Hybrid Electric Vehicles in the US. ...
June 2012
85 pages
Analyzing the Market for Refined Petroleum Products in the US
US$ 350.00
The United States is the largest, most sophisticated producer of refined petroleum products in the world, with nearly 20 million ... , amongst others. Aruvians Rsearch analyzes the refined petroleum products market in the US in its research offering Analyzing the Market for Refined Petroleum Products in the US. ...
June 2012
105 pages
Analyzing Geothermal Power in the US
US$ 400.00
... the powerful combination of high energy prices and growing state government support. The United States Department of Energy Geothermal Technologies Program ... of development. Aruvians Rsearch analyzes the Geothermal Power in the US in its latest research offering Analyzing Geothermal Power in the US. The report ...
June 2012
195 pages
Biogen: Teriflunomide Does Not TOWER Over BG-12!
US$ 90.00
Top-line data from PhIII trial, TOWER of Sanofi’s Aubagio (teriflunomide, R, RRMS, PDUFA: 3Q12) reaffirms our take on BG-12 (Dimethyl fumerate, R, Est. ... details, please read our report released on June 1st , 2012 on Biogen (BIIB), titled “Teriflunomide Does Not TOWER Over BG-12”
May 2012
4 pages
AMGEN: Innovation + Emerging Market – A Balanced Approach!
US$ 140.00
... boosted Amgen’s (AMGN) pipeline, while Mustafa Nevzat pharma (MN pharma, pvt., Turkey) is a strategic move to increase its presence in the growing emerging/ international markets ... read our report released on May 29th, 2012 on AMGN, titled “Innovation + Emerging Market – A Balanced Approach”
May 2012
7 pages
Chocolate Candy in the U.S., 9th Edition
US$ 3,750.00
... from the competition. From this perspective, Chocolate Candy in the U.S. examines the current state of the industry and where the growth ... footprints Continued innovation in packaging and flavors by major and niche chocolate manufactures alike Increased marketing support and advertising expenditures Rising ...
May 2012
164 pages
Debit Cards in the U.S., 4th Edition
US$ 4,295.00
... overdraft fees—are under assault. As an integral part of consumer checking accounts, debit card transactions drive interchange revenue and are linked to overdraft ... the impact these trends have on consumers and merchants. While we expect debit to remain a checking account lynchpin, the bottom line is that the ...
May 2012
152 pages
REGENERON - Diversified Pipeline can Buffer the Setback
US$ 140.00
Despite the setback in the pipeline – negative recommendation from FDA advisory committee on ... franchise should be able to buffer some setbacks in the pipeline. The FDA advisory panel voted 11-0 against approval of the ... , released on May 14, 2012 on REGN, titled “Diversified Pipeline can Buffer the Setback”.
May 2012
6 pages
U.S. Market for Spinal Implants & VCF 2012
US$ 6,495.00
The U.S. market for spinal implants includes segments for traditional cervical and thoracolumbar fixation devices, ... compression fracture (VCF) treatment and spinal electrical stimulation. Despite multiple challenges, growth is expected in many market segments, as the patient demographics in the ...
May 2012
438 pages
U.S. Market for Orthopedic Braces & Support Devices 2012
US$ 7,495.00
... market is expected to exceed $2.48 billion by 2018. The U.S. bracing and supports market includes: knee bracing and supports, ankle bracing and supports, spinal orthoses, back soft goods, upper extremity bracing and soft goods pain management (including cold therapy and pain infusion ...
May 2012
290 pages
INCYTE: JAKAFI / JAKAVI to Drive Sustainable Profitability
US$ 140.00
Incyte (INCY) reported net revenues of $19.3m of the only approved drug for Myelofribrosis (MF), JAKAFI / JAKAVI (ruxolitinib, JAK 1/2 inhibitor, PhII/III in PV/ET; partnered with Novartis for ... , please read our report released on May 2, 2012 on INCY, titled “JAKAFI / JAKAVI to Drive Sustainable Profitability”
May 2012
3 pages
Analyzing the Market for Pigments in US
US$ 400.00
... few of the top players in the market. Aruvians Rsearch analyzes the Pigments market in the US in its research offering Analyzing the Market for Pigments in US. The report is a complete analysis ...
May 2012
90 pages
Analyzing the Battery Market in US
US$ 400.00
... five years. The United States is the single biggest market in the world for batteries with a market size of $5 billion annually. The US industrial market is estimated to be $600 million ...
May 2012
100 pages
Analyzing the Market for Pulp & Paper Chemicals in the US
US$ 400.00
... environmentally-friendly profiles. Aruvians Rsearch analyzes the Pulp & Paper Chemicals market in the US in its research offering Analyzing the Market for Pulp & Paper Chemicals in the US. The ...
May 2012
115 pages
Residential Water Treatment Market: United States
US$ 1,000.00
... and Gamble and others. Market Definition by Product For the purposes of this study a residential water treatment (RWT) system is defined as: Point-of- ... are also knows as jug filters in certain parts of the world. Water is filtered by gravity through a filter cartridge, mostly made up of carbon. Pitchers ...
April 2012
CELGENE – Revlimid Sales Disappoints, but Long Term Prospects Intact!
US$ 90.00
Though Q1’12 earnings were disappointing (flat growth of Revlimid), we expect Celgene (CELG) should able to meet its FY12 guidance (Total rev.: $5.4-$5.6b ... read our report released on 27th April, 2012 on CELG titled, “Revlimid Sales Disappoints, but Long Term Prospects Intact!”
April 2012
4 pages
ALEXION: Soliris’ Label Expansion & Diversification to Perk ALXN Up!
US$ 140.00
... Hemolytic Uremic Syndrome (aHUS) indication, and label expansion in other rare and high unmet need indications of Soliris; we expect the growth trajectory continues ... , please read our report released on April 25, 2012 on ALXN, titled “Soliris’ Label Expansion & Diversification to Perk ALXN Up!”
April 2012
5 pages
Millennials in the U.S.
US$ 3,850.00
... . The challenge for marketers is to leverage this common ground to find Millennials whoever and wherever they are and engage them no matter ... The report begins with an overview of the trends shaping the adult Millennial market, significant marketing opportunities and projections of market growth. It continues ...
April 2012
178 pages
2012 US Hemostasis Diagnostics Market Outlook: Growth Opportunities and Strategies
US$ 6,800.00
Report Highlights Comprehensive 424-page analysis of the US hemostasis market. Major issues pertaining to the US hemostasis laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. Ten-year volume and ...
April 2012
424 pages
Cosmeceuticals in the U.S, 6th Edition
US$ 3,750.00
... growth in 2010 and 4% growth in 2011. This upswing puts U.S. retail sales of cosmeceuticals at $9.7 billion in 2011, with ongoing annual sales gains expected to boost ... completely updated Packaged Facts report examines the market for cosmeceutical products within the context of broader HBC trends in new product ...
April 2012
238 pages
2012 US Flow Cytometry Market Outlook: Growth Opportunities and Strategies
US$ 4,720.00
This report presents a comprehensive analysis of the US flow cytometry market, including: Major issues pertaining to the US flow cytometry practice, as well as key economic, ... with significant market impact during the next five years. Five-year volume and sales forecasts for major flow cytometry tests ...
April 2012
174 pages
INCYTE: Cheers for INCY - JAKAVI Receives CHMP Nod!
US$ 90.00
Incyte/ Novartis’ JAKAVI (ruxolitinib, JAK 1/2 inhibitor, Registered for MF; PhII ... triggers $40m milestone payment from Novartis (Ex-US rights), and INCY will received a second payment of $60m upon an achievement ... our report released on April 20, 2012 on INCY, titled “Cheers for INCY - JAKAVI Receives CHMP Nod!”
April 2012
2 pages
Cat Population and Cat Owner Trends
US$ 2,000.00
... and Cat Owner Trends, Packaged Facts focuses on the population of pet cats, cat owner demographics, and cat owner psychographics in the U.S. market. The report offers a present-day and historical analysis of cat owners, examining trends in this cohort's financial, household, regional, ethnic, and ...
April 2012
70 pages
Merck - Celltrion filed first mAB Biosimilar in Europe: Remicade Challenged
US$ 90.00
Celltrion filed infliximab biosimilar (CT-P13) in Europe and was accepted for review by EMA. It is the first biosimilar mAb to be filed for approval in Europe. The patent ... Celltrion conducted PhI and PhIII clinical trials with the duration of 12 months in more than 850 patients. It has already filed Infliximab ...
April 2012
1 pages
